Bioretec (FRA:0TN) Marketable Securities: €3.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioretec Marketable Securities?

Bioretec FRA:0TN +1.03% Marketable Securities is €3.04 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Bioretec's Marketable Securities for the quarter that ended in Dec. 2025 was €3.04 Mil.

Bioretec's annual Marketable Securities declined from Dec. 2023 (€3.13 Mil) to Dec. 2024 (€2.45 Mil) but then increased from Dec. 2024 (€2.45 Mil) to Dec. 2025 (€3.04 Mil).

Bioretec  (FRA:0TN) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Bioretec Marketable Securities Related Terms

Bioretec Marketable Securities Historical Data

* Premium members only.

The historical data trend for Bioretec's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioretec Marketable Securities Chart

Bioretec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 6.46 1.02 3.13 2.45 3.04

Bioretec Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 0.00 2.45 0.00 3.04

Bioretec Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €3.04 Mil mean?
Bioretec (FRA:0TN) has a Marketable Securities of €3.04 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bioretec and its competitors.
Is Bioretec's Marketable Securities too high?
Bioretec's current Marketable Securities is €3.04 Mil.
How does Bioretec's Marketable Securities compare to ABT and SYK?
Bioretec's Marketable Securities of €3.04 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Bioretec and its competitors. Bioretec's current Marketable Securities is €3.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioretec stock overvalued right now?
Based on GuruFocus' analysis, Bioretec (FRA:0TN) is currently considered Possible Value Trap. The stock's GF Value™ is €0.19, compared to a current price of €0.02 — trading 89.7% below its estimated fair value. The current Marketable Securities is €3.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Bioretec (FRA:0TN), the current Marketable Securities is €3.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioretec Business Description

Other Exchanges BRETEC:Finland
Address Yrittajankulma 5, Tampere, FIN, 33710
Bioretec Ltd is a medical device company focusing on the development of bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. It has developed the following product lines: RemeOs and Activa. RemeOs is based on a high-performance magnesium alloy and hybrid composite, introducing absorbable materials for enhanced surgical outcomes. The RemeOs implants (RemeOs Screw Lag, RemeOs Screw Lag Solid, RemeOs Screw FT, etc.) are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The Activa implants (ActivaPin, ActivaNail, ActivaScrew, etc.) are based on fully absorbable biopolymer products that facilitate natural bone healing without requiring removal surgery.